New inhaled treatment tested to fight stubborn lung infections
NCT ID NCT06663176
Summary
This early-stage study is testing the safety and initial effectiveness of a new inhaled nitric oxide treatment called RESP30X. It is for adults with a lung condition called non-cystic fibrosis bronchiectasis who have persistent, high levels of certain bacteria in their lungs. Participants will use a nebulizer to inhale the study drug multiple times a day for 28 days to see if it can help control these infections.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-CYSTIC FIBROSIS BRONCHIECTASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ARENSIA Exploratory Medicine
Kyiv, Ukraine
Conditions
Explore the condition pages connected to this study.